The PORB antibody (e.g., PACO52266) is a polyclonal antibody raised in rabbits against recombinant PorB protein from Neisseria meningitidis serogroup B. PorB, a β-barrel transmembrane protein, facilitates ion transport across bacterial membranes and modulates host immune responses . Its structural and functional diversity across bacterial strains makes it a focal point for studies on microbial adaptation and therapeutic targeting .
Key specifications of the PORB Polyclonal Antibody (PACO52266) include:
This antibody exhibits high specificity for PorB’s extracellular loops, which are critical for ion selectivity and immune evasion .
PorB contributes to bacterial survival through:
Antibiotic Resistance: Alters outer membrane permeability to reduce drug uptake .
Immune Evasion: Binds host complement regulators (e.g., factor H) to inhibit opsonization .
TLR Activation: Acts as a Toll-like receptor (TLR) 1/2 agonist, triggering pro-inflammatory cytokine production .
Studies show PorB variants from N. gonorrhoeae (Gc) and N. meningitidis (Nm) share 70–78% sequence identity, enabling cross-reactive antibody responses .
The PORB antibody has been instrumental in elucidating PorB’s adjuvant properties:
Antigen Trafficking: Enhances antigen deposition on follicular dendritic cells (FDCs) by 2.5-fold compared to CpG adjuvants, promoting B-cell affinity maturation .
Cellular Immunity: Drives Th1-biased responses (high IgG2a/IgG1 ratios) when delivered via viral replicon particles (VRPs), unlike alum-based Th2 polarization .
Bactericidal Activity: Anti-PorB monoclonal antibodies demonstrate in vitro killing of Gc (e.g., 80% killing of strain FA1090 at 10 µg/mL) .
4CMenB Vaccine: Elicits cross-reactive PorB antibodies that reduce Gc colonization in murine models .
Mucosal Immunity: Intranasal delivery of PorB-containing outer membrane vesicles (OMVs) induces mucosal IgA (mean titer >1:160) and serum bactericidal activity .
Human monoclonal antibodies (e.g., 01C05, 02G22) targeting conserved PorB epitopes show cross-species neutralizing activity .
Antigenic Diversity: PorB’s hypervariable loops necessitate multivalent vaccine formulations .
Antibody Cross-Reactivity: Low IgG/IgA titers against heterologous PorB variants (<1:100) highlight immunodominance challenges .
Adjuvant Optimization: Combining PorB with nanoparticle delivery systems may enhance cellular uptake and durability of immune responses .